

**PRODUCT INFORMATION**

<b>Common Name</b>	1F5, CDX-1127
<b>Conjugate</b>	Unconjugated
<b>Synonyms</b>	CD27;TNFRSF7;S152;T14;Tp55
<b>Applications</b>	ELISA; Flow Cyt
<b>Recommended Dilutions</b>	ELISA 1:5000-10000; Flow Cyt 1:100
<b>Formulation &amp; Reconstitution</b>	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
<b>Host Species</b>	Homo sapiens
<b>IgG type</b>	Human IgG1 - kappa
<b>Reactivity</b>	Human
<b>Target</b>	CD27
<b>Uniprot ID</b>	P26842
<b>Description</b>	Anti-CD27 (varlilumab biosimilar) mAb
<b>Delivery</b>	In Stock
<b>Storage&amp;Shipping</b>	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
<b>Background</b>	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
<b>Usage</b>	Research use only



## Human CD27, hFc Tagged protein ELISA

0.2 µg of CD27, hFc Tagged protein per well




Figure 1. ELISA plate pre-coated by 2 µg/ml (100 µL/well) Human CD27, hFc tagged protein (PME100475) can bind Anti-CD27 Neutralizing antibody in a linear range of 3.2-80.0 ng/ml. In order to specifically detect BME100018, mouse anti-human Fab-specific antibody was used as detection antibody.

## Anti-CD27 (varlilumab biosimilar) mAb ELISA

0.2 µg of CD27, mFc-His Tagged protein per well






Figure 2. ELISA plate pre-coated by 2 µg/ml (100 µl/well) Human CD27, mFc-His tagged protein ([getskuurl sku="PME100013"]]) can bind Anti-CD27 Neutralizing antibody in a linear range of 0.64-16.0 ng/ml.



**A****CD27****B****irrelevant protein**

**Figure 3.** HEK293 cell line transfected with irrelevant protein (**B**) and human CD27 protein (**A**) were surface stained with anti-CD27 neutralizing antibody 1 $\mu$ g/ml (varlilumab) followed by Alexa 488-conjugated anti-human IgG secondary antibody.

